Clinical course of patients with cisplatin (CDDP)-associated neuropathy compared to other neurotoxic chemotherapy
| Autor: | Brian A. Costello, Costantine Albany, Sara I Edwards, Eric G. Wolfe, Nina D. Wagner-Johnston, Lina M Sego, Kayla Marie Lazzara, Deirdre R. Pachman, Christin I. Snow, Charles L. Loprinzi, Travis J. Dockter, Nasser H. Hanna, Lawrence H. Einhorn |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Cisplatin Cancer Research medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Clinical course Neurotoxicity medicine.disease stomatognathic diseases Peripheral neuropathy Internal medicine medicine Outcome data business neoplasms Testicular cancer medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 37:e23078-e23078 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | e23078 Background: There are limited patient (pt) reported outcome data regarding CDDP neurotoxicity. Methods: CDDP-induced peripheral neuropathy was evaluated in pts with testicular cancer planning to receive CDDP (20 mg/m2/d for 5 days) for ≥ 3 cycles. Neurotoxicity was assessed with the EORTC QLQ-CIPN20 tool before each CDDP cycle and every 2-4 months after, out to 18 months. We compared these data to our studies evaluating pts receiving doxorubicin/cyclophosphamide (AC), paclitaxel and oxaliplatin. The total score of the EORTC QLQ-CIPN20, each of the three subscale scores and each individual item was computed following the standard scoring algorithm and converted to a 0-100 scale. Descriptive statistics and graphical plots were utilized. Results: 54 pts receiving CDDP (mean age 33 years) and 18 pts receiving AC were evaluated. Following completion of CDDP, neuropathy symptoms (sensory neuropathy score and numbness/tingling in toes/feet) worsened for about 6 months (consistent with the so-called “coasting phenomena”), similar to what had previously been seen with oxaliplatin (but different than what had been seen with paclitaxel). For CDDP pts, during therapy, numbness and tingling in fingers/hands were more prominent, than the same symptoms in the toes/feet. After therapy was completed, numbness, and tingling became more prominent in toes/feet, but improved in the fingers/hands. After stopping therapy, shooting/burning pain did not worsen in upper or lower extremities. During therapy, CDDP pts had less problems than had previously been seen with oxaliplatin or paclitaxel, maybe because of the younger ages of the CDDP pts. With AC, all of the CIPN-20 sensory neuropathy scores were better than was seen in the pts receiving CDDP and also in pts receiving paclitaxel and oxaliplatin in previous evaluations. Conclusions: CDDP-induced neuropathy is more similar to oxaliplatin-induced neuropathy than paclitaxel-induced neuropathy. AC chemotherapy pts do not have substantial changes in CIPN 20 scores, consistent with the CIPN 20 instrument being a measure of chemotherapy-induced neuropathy, as opposed to more general chemotherapy-induced toxicities. Clinical trial information: NCT02677727. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|